tbuckley/cabot-search huggingface dataset:
Abstract 16794: Variation in Achievable Chest Compression Depth Assessed by Cardiac MRI
Authors: Sverre Nestaas, Vigdis Rosseland, Knut Haakon Steensaeth, Jo Kramer-Johansen
Journal: Circulation (2015)

Introduction: Recommended chest compression depth during cardiopulmonary resuscitation (CPR) for adults was increased to 5-6 cm in 2010. According to the cardiac pump theory each compression squeezes blood from the heart and the amount of blood per compression would be expected to be limited by the blood filled structures directly underneath the compression point. Methods: Cardiovascular MR (CMR) survey axial scans acquired from consenting patients referred for CMR were analyzed. We measured the external anterior-posterior (AP) diameter (AP) and the cumulative height of blood-filled structures in the perpendicular line in an axial plane from the compression point in the center of the inter-nipple line (INL) (Compression line). Results are means with standard deviation (SD) and mean differences with 95 % confidence intervals (CI), P-values from unpaired, two-sided t-test. Results: We included 144 patients, age 52 (17), 110 (76 %) males, 74 (60 %) having one or more pathological finding from the exam. The most prominent structure identified in the studied midline was (decreasing order): Left Atrium (41 %), Right Ventricle (31 %), Right Atrium (12 %), Left Ventricular Outflow Tract (LVOT)/Root of Aorta (8 %), Pulmonary Outflow Tract (2 %), other (6 %). Altogether, LVOT was present in 35 % and Left Ventricle in only 2 % of compression lines. Mean (SD) AP diameter for males and females was 25 (2) cm and 22 (2) cm (mean difference 2 cm (95 % CI 1, 3; P&lt;0.001)), and the blood filled length of the compression line (APblood) were 6.5 cm (2) and 4.7 cm (2) (mean difference 1.8 cm (95 % CI 1.1, 2.5, P&lt;0.001)), respectively. This comprised 22 % (10) and 26 % (7) of the AP diameter, for men and women, respectively. In a linear regression gender, body mass index (BMI), but not pathological findings were significant predictors of external AP diameter. Only gender was found to predict APblood. Conclusions: In the average male 5-6 cm chest compression depth at the level of the INL seems feasible, but for over half of the women compressions deeper than 5 cm would probably compress connective and muscle tissue rather than just squeeze blood from the heart, even though the blood-filled proportion of the AP diameter was larger in women than in men.
P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study
Authors: D. Spigel, J. Vansteenkiste, M. Reck, H. Wakelee, M. Özgüroğlu, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, L. Paz-Ares, L. Poole, C. Wadsworth, P. Dennis, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)
Authors: J.L. Evelhoch, R. Mogg, R. Cristescu, D. Aurora-Garg, L.Q. Chow, S. Loi, D.V.T. Catenacci, U.A. Matulonis, P.A. Ott, E.S. Antonarakis, C.H. Poehlein, A. Joe, S.M. Keefe, P. Kang, V. Karantza, J. Cheng, E.H. Rubin
Journal: Annals of Oncology (2018)
Unbiased genomewide screening of circulating plasma DNA for cancer detection
Authors: L. Lenaerts, N. Brison, M. Neofytou, H. Che, L. Dehaspe, M. Verheecke, C. Maggen, B. Dewaele, S. Vanderschueren, V. Vandecaveye, P. Vandenberghe, J. Vermeesch, F. Amant
Journal: Annals of Oncology (2018)
P2.11-23 Risk Perception Among a Lung Cancer Screening Population
Authors: J. Turner, G. Pond, A. Tremblay, M. Johnston, G. Goss, G. Nicholas, S. Martel, R. Bhatia, G. Liu, H. Schmidt, M. Tammemagi, S. Puksa, S. Atkar-Khattra, M. Tsao, S. Lam, J. Goffin
Journal: Journal of Thoracic Oncology (2018)
P2.06-11 A Phase I/II Study of Intrapleural Ad-SGE-REIC Administration in Patients with Refractory Malignant Pleural Mesothelioma
Authors: Y. Goto, Y. Ohe, K. Kuribayashi, T. Nakano, M. Okada, S. Toyooka, H. Kumon, Y. Nakanishi
Journal: Journal of Thoracic Oncology (2018)
P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
Authors: L. Byers, K. Gold, J. Peguero, M. Johnson, J. Nieva, W. Harb, A. Chiappori, J. Strauss, D. Gerber
Journal: Journal of Thoracic Oncology (2018)
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)
Authors: R.K. Das, L. Furchtgott, F.-S. Ou, D. Swanson, B. Hayete, B. Harms, D. Cunha, J. Latourelle, D. Wuest, I. Khalil, C. Washburn, K. Rich, C.D. Blanke, J. Meyerhardt, D. Niedzwiecki, A. Nixon, E.M. O’Reilly, F. Innocenti, H.-J. Lenz, A. Venook
Journal: Annals of Oncology (2018)
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma
Authors: Matthew S. Davids, Gottfried von Keudell, Craig A. Portell, Jonathon B. Cohen, David C. Fisher, Francine Foss, Andrew W. Roberts, John F. Seymour, Rod A. Humerickhouse, Constantine S. Tam
Journal: Journal of Clinical Oncology (2018)
P1.01-46 Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
Authors: C. Kim, L. Xi, C. Cultraro, T. Pham, N. Roper, M. Bagheri, A. Rajan, J. Beeler, G. Jones, M. Raffeld, U. Guha
Journal: Journal of Thoracic Oncology (2018)
P1.13-14 The Molecular Landscape of Lung Adenocarcinomas with Activating EGFR Gene Mutations Determined by Targeted-Sequencing
Authors: M. Nicoś, K. Wojas-Krawczyk, P. Krawczyk, P. Calka, M. Ciesielka, K. Reszka, J. Milanowski
Journal: Journal of Thoracic Oncology (2018)
Preliminary results of phase I/II study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL)
Authors: F. Ma, J. Li, J. Ren, X. Zhang, F. Wang, X. Guo, J. Zhang, D. Wang, Q. Liu, J. Luo
Journal: Annals of Oncology (2018)
P1.01-86 BTCRC-LUN15-017: Phase-Ib Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC after Progression on Platinum Based Therapy
Authors: A. Shergill, M. Furqan, J. Malhotra, L. Liu, N. Bose, C. Belani, L. Feldman
Journal: Journal of Thoracic Oncology (2018)
Effect of Docosahexaenoic Acid Supplementation vs Placebo on Developmental Outcomes of Toddlers Born Preterm
Authors: Sarah A. Keim, Kelly M. Boone, Mark A. Klebanoff, Abigail Norris Turner, Joseph Rausch, Mary Ann Nelin, Lynette K. Rogers, Keith Owen Yeates, Leif Nelin, Kelly W. Sheppard
Journal: JAMA Pediatrics (2018)

Intake of dietary docosahexaenoic acid (DHA) among toddlers is low. Supplementation may benefit developmental outcomes of toddlers who were born preterm.To determine whether 6 months of daily DHA supplementation improves developmental outcomes of toddlers who were born preterm.A randomized, fully masked, placebo-controlled trial was conducted from April 26, 2012, to March 24, 2017, at a large US pediatric academic center with 9 neonatal intensive care units. Children born at less than 35 weeks' gestation who were 10 to 16 months corrected age underwent 6 months of intervention. Of 2363 children assessed, 982 were eligible, 605 declined, and 377 enrolled and were randomized. Analyses were according to intent to treat.One-to-one allocation to receive daily microencapsulated DHA, 200 mg, and arachidonic acid (AA), 200 mg (DHA+AA), or microencapsulated corn oil (placebo).The primary outcome specified a priori was Bayley Scales of Infant and Toddler Development, third edition (Bayley-III), cognitive composite score at 16 to 22 months corrected age. Secondary outcomes were Bayley-III language and motor composite scores and Infant Behavior Questionnaire-Revised and Early Childhood Behavior Questionnaire effortful control and activity level scores. Subgroup analyses defined a priori were by income, sex, and birth weight.Among 377 children randomized and included in the analysis (182 girls and 195 boys; median corrected age, 15.7 months), 338 children (89.7%) had complete data on the primary outcome. Bayley-III cognitive scores did not differ between the DHA+AA and placebo groups (difference in change, 0.5 [95% CI, -1.8 to 2.8]; effect size, 0.05; P = .66). Assignment to the DHA+AA group had a small to medium negative effect on Bayley-III language scores among children with lower birth weights (eg, a child with a birth weight of 1000 g assigned to receive DHA+AA experienced a 4.1-point relative decrease, while a child assigned to placebo did not; P = .03 for interaction). Supplementation had a similar negative effect on effortful control scores among children with annual household incomes greater than $35 000 (difference in change, -0.3 [95% CI, -0.4 to -0.1]; effect size, -0.37; P = .01). Bayley-III motor scores and activity level scores were unaffected.Daily supplementation with 200 mg of DHA and 200 mg of AA for 6 months resulted in no improvement in cognitive development and early measures of executive function vs placebo, and may have resulted in negative effects on language development and effortful control in certain subgroups of children. These findings do not support DHA supplementation in the second year of life for children who are born preterm.ClinicalTrials.gov Identifier: NCT01576783.
Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial
Authors: David B. Antcliffe, Katie L. Burnham, Farah Al-Beidh, Shalini Santhakumaran, Stephen J. Brett, Charles J. Hinds, Deborah Ashby, Julian C. Knight, Anthony C. Gordon
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

There remains uncertainty about the role of corticosteroids in sepsis with clear beneficial effects on shock duration, but conflicting survival effects. Two transcriptomic sepsis response signatures (SRSs) have been identified. SRS1 is relatively immunosuppressed, whereas SRS2 is relatively immunocompetent.We aimed to categorize patients based on SRS endotypes to determine if these profiles influenced response to either norepinephrine or vasopressin, or to corticosteroids in septic shock.A post hoc analysis was performed of a double-blind, randomized clinical trial in septic shock (VANISH [Vasopressin vs. Norepinephrine as Initial Therapy in Septic Shock]). Patients were included within 6 hours of onset of shock and were randomized to receive norepinephrine or vasopressin followed by hydrocortisone or placebo. Genome-wide gene expression profiling was performed and SRS endotype was determined by a previously established model using seven discriminant genes.Samples were available from 176 patients: 83 SRS1 and 93 SRS2. There was no significant interaction between SRS group and vasopressor assignment (P = 0.50). However, there was an interaction between assignment to hydrocortisone or placebo, and SRS endotype (P = 0.02). Hydrocortisone use was associated with increased mortality in those with an SRS2 phenotype (odds ratio = 7.9; 95% confidence interval = 1.6-39.9).Transcriptomic profile at onset of septic shock was associated with response to corticosteroids. Those with the immunocompetent SRS2 endotype had significantly higher mortality when given corticosteroids compared with placebo. Clinical trial registered with www.clinicaltrials.gov (ISRCTN 20769191).
What Is the Relationship between Dopamine and Effort?
Authors: Mark E. Walton, Sebastien Bouret
Journal: Trends in Neurosciences (2018)

The trade-off between reward and effort is at the heart of most behavioral theories, from ecology to economics. Compared to reward, however, effort remains poorly understood, both at the behavioral and neurophysiological levels. This is important because unwillingness to overcome effort to gain reward is a common feature of many neuropsychiatric and neurological disorders. A recent surge in interest in the neurobiological basis of effort has led to seemingly conflicting results regarding the role of dopamine. We argue here that, upon closer examination, there is actually striking consensus across studies: dopamine primarily codes for future reward but is less sensitive to anticipated effort cost. This strong association between dopamine and the incentive effects of rewards places dopamine in a key position to promote reward-directed action.
Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model
Authors: H. Wakelee, J. Aredo, S. Vali, N.K. Singh, S.V. Vasista, U. Mitra, T. Abbasi, S.K. Padda
Journal: Annals of Oncology (2018)
Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3
Authors: M. Cristofanilli, D.J. Slamon, J. Ro, I. Bondarenko, S.-A. Im, N. Masuda, M. Colleoni, A. DeMichele, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, F. André, K. Puyana Theall, X. Huang, C. Giorgetti, C. Huang Bartlett, N.C. Turner
Journal: Annals of Oncology (2018)
Randomized phase II study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small cell lung cancer (CLEAR study)
Authors: R. Koyama, H. Udagawa, E. Sugiyama, K. Komuta, M. Mori, T. Yokoyama, T. Sasaki, H. Saito, H. Ishida, H. Nakagawa, A. Sekine, A. Tamura, M. Shingyoji, K. Mizuno, A. Nakamura, A. Kinoshita, T. Yamanaka, K. Goto
Journal: Annals of Oncology (2018)
A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
Authors: E.E.W. Cohen, K.J. Harrington, D.S. Hong, R. Mesia, I. Brana, P. Perez Segura, T. Wise-Draper, M.L. Scott, P.D. Mitchell, G.M. Mugundu, P. McCoon, C.E. Cook, M. Mehta, U. Keilholz
Journal: Annals of Oncology (2018)
MA08.01 Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)
Authors: Z. Yang, Y. Zhang, R. Li, A. Yisikandaer, B. Ren, J. Sun, J. Li, L. Chen, R. Zhao, J. Zhang
Journal: Journal of Thoracic Oncology (2018)
Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013
Authors: Minghuan Wang, Xiang Luo, Shabei Xu, Wenhua Liu, Fengfei Ding, Xiaoxiang Zhang, Liang Wang, Jian Liu, Jianping Hu, Wei Wang
Journal: The Lancet Respiratory Medicine (2018)
The Illness We Carry
Authors: Payal Chandresh Shah
Journal: JAMA Cardiology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
P1.03-01 Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer
Authors: S. Feng, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Potential clinical management changes in patients harboring locally advanced squamous-cell carcinoma of head and neck by incorporating pre and post chemoradiotherapy 18.FDG PET/CT: A prospective trial
Authors: U.R. Nicolau, A.C.M.D. Queiroz, T. Felismino, E.P.N. Lima, V.H.F. Jesus, L. Cezana, M.S. Alves, A.C.A. Pellizzon, P.N. Pinto, G.M. Porto, G.B. Carvalho, C.A.L. Pinto, V.S.E. Silva, A.P. Guimarães, T.B. Oliveira, M.K. Ikeda, T.F. Paiva, P.C. Bes, L.P. Kowalski
Journal: Annals of Oncology (2018)
Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Authors: Y. Li, J.X. Sun, J. Skoletsky, C. Milbury, C. Burns, W.-K. Yip, N. Dewal, J. He, J. Tuesdell, E. Peters, E. Schleifman, J. Noe, S. Jenkins, J.A. Elvin, G. Otto, D. Lipson, J.S. Ross, V.A. Miller, M. Doherty, C. Vietz
Journal: Annals of Oncology (2018)
MA02.01 ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events
Authors: T. Ng, D. Smith, R. Mushtaq, T. Patil, A. Dimou, S. Yang, Q. Liu, X. Li, C. Zhou, F. Yan, I.A. Bowman, S. Liu, R. Doebele, D. Aisner, S. Ren, R. Camidge
Journal: Journal of Thoracic Oncology (2018)
Health-related quality of life in randomized controlled trials: A systematic review of prognostic significance
Authors: J. Mierzynska, M. Pe, C. Piccinin, F. Martinelli, C. Coens, C. Gotay, A.M.M. Eggermont, M. Groenvold, J. Reijneveld, L. Dirven, A. Bottomley
Journal: Annals of Oncology (2018)
Abstract 12654: PBI-4050 Therapy Selectively Improves Pulmonary Hypertension, Lung Remodeling and Right Ventricular Function in Heart Failure With Reduced Ejection Fraction
Authors: Quang T Nguyen, Martin Sirois, Angelo Calderone, Jean-Claude Tardif, Yanfen Shi, Lyne Gagnon, Jocelyn Dupuis
Journal: Circulation (2016)

Introduction: There is currently no approved treatment for the most prevalent form of PH that is associated with left heart disease (Group II PH). Heart failure with reduced ejection fraction (HFrEF) causes lung remodeling characterized by myofibroblasts proliferation and fibrosis leading to a restrictive lung syndrome contributing to PH and RV dysfunction. Hypothesis: We evaluated PBI-4050, a novel first-in-class agent with anti-fibrotic and anti-proliferative actions, for the treatment of PH in a model of HFrEF. Methods: HFrEF was induced by myocardial infarction (MI) after coronary artery ligation in rats. Two weeks after surgery, sham-operated and MI groups were treated with PBI-4050 (200 mg/kg/day by gavage) or with saline for 3 weeks. Animals were analyzed according to pathological infarct size into large MI (≥35% LV) and small to medium MI (&lt; 35%). Hemodynamic evaluation was performed with microtip cathethers and lung function testing evaluated with a Flexivent respirator. Cardiac ultrasound was performed at 2 weeks and at 5 weeks. Scar size and lung fibrosis were quantified by histology. Results: Pathological infarct size correlated with echocardiographic wall motion score index (r 2 =0.73, p&lt;0.001). Large MI (≥35% LV) resulted in PH and RVH with a restrictive lung syndrome. For a similar infarct size, PBI-4050 did not affect LV function but markedly reduced PH and RVH. The compensatory increase in RV contractility was normalized by PBI-4050. PBI-4050 reduced lung remodeling evidenced by a reduction in lung weight and improved respiratory compliance. Finally, lung fibrosis was reduced by PBI-4050 with histological evidence of reduced alveolar wall cellular proliferation. Conclusions: PBI-4050 effectively reduces PH and RVH in HFrEF by reducing lung fibrosis and remodeling. This novel agent decreases the associated restrictive lung syndrome and recovers RV function without affecting LV function. PBI-4050 is a promising therapy for group II PH.
Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience
Authors: G. Bruixola, J. Caballero Daroqui, A.J. Cunquero Tomas, S. Sandiego, J. García Sánchez, S. Blasco, S. Ochenduszko, A. Iranzo, J. Lavernia, A. Berrocal Jaime, M. Pastor Borgoñón
Journal: Annals of Oncology (2018)
Neoadjuvant eribulin plus carboplatin vs. paclitaxel plus carboplatin in patients with triple-negative breast cancer (TNBC)
Authors: L. Gigolaeva, P. Krivorotko, S. Khadzhimatova, E. Zhiltsova, S. Yerechshenko, M. Nikitina, V. Ni, A. Emelyanov, E.N. Imyanitov, A.P. Sokolenko, T. Tabagua
Journal: Annals of Oncology (2018)
<i>Notes from the Field:</i> Recurrence of a Multistate Outbreak of <i>Salmonella</i> Enteritidis Infections Linked to Contact with Guinea Pigs — Eight States, 2015–2017
Authors: Scott Robertson, Alexis Burakoff, Lauren Stevenson, Bradley Tompkins, Kane Patel, Beth Tolar, Laura Whitlock, Jennifer House, Linda Schlater, Tonya Mackie, Brenda Morningstar-Shaw, Megin Nichols, Colin Basler
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Pet Store Chain 1 Pet Store Chain
P1.09-18 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma
Authors: W. Wang, C. Xu, R. Huang, C. He, Y. Zhu, W. Zhuang, Y. Huang, M. Fang, Y. Chen, G. Chen, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P2.16-15 Toxicities and Survival after Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors
Authors: B. Atalar, T. Mustafayev, T. Sio, B. Sahin, G. Gungor, G. Aydin, B. Yapici, E. Ozyar
Journal: Journal of Thoracic Oncology (2018)
Repeated mutKRAS ctDNA measurements in patients with advanced pancreatic cancer patients: Kinetics, response prediction and therapy monitoring in comparison to protein-based tumor markers
Authors: S. Kruger, V. Heinemann, C. Ross, F. Diehl, S. Ormanns, S. Liebmann, C.B. Westphalen, M. Haas, A. Jung, T. Kirchner, M. von Bergwelt-Baildon, S. Holdenrieder, S. Boeck
Journal: Annals of Oncology (2018)
P2.15-01 CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer
Authors: K.G. Babu, D. K, B. Balakrishnan, M. Biswas, A. Prasath, P. Radhakrishnan, A. Chatterjee, S. Thyiagarajan, P. Chaudhury
Journal: Journal of Thoracic Oncology (2018)
Molecular profiling of PDAC and response to chemotherapy: An update from the COMPASS trial
Authors: G.M. O’Kane, S. Fischer, R.E. Denroche, G.H. Jang, A. Zhang, A. Dodd, H. Albaba, S. Moura, S. Holter, K. Aung, R.C. Grant, P. Krzyzanowski, E. Elimova, N. Dhani, D. Hedley, F. Notta, J.M. Wilson, S. Gallinger, J.J. Knox
Journal: Annals of Oncology (2018)
Palliative care in advanced cancer: A clinical and ethical goal achieved?
Authors: J.C. Sanchez, R. Gomez-Bravo, A.M. Morito Aguilar, A. Royuela, B. Núñez García, T. Tojar, A. Ruano Ravina, C. Parejo, B. Cantos, M. Provencio Pulla
Journal: Annals of Oncology (2018)
Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey
Authors: M. Lambertini, M. Di Maio, F. Poggio, O. Pagani, G. Curigliano, L. Del Mastro, S. Paluch-Shimon, S. Loibl, A.H. Partridge, H.A. Azim, F.A. Peccatori, I. Demeestere
Journal: Annals of Oncology (2018)
OT-1096: A first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral tregs in a humanized TNBC-PDX model
Authors: O. Orwar, I. Lowstedt, K. Andersson, G. Gannedahl, G. Willman, M. Davidsson, W. Stafford, C. Trkulja
Journal: Annals of Oncology (2018)
P3.03-08 Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients
Authors: C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P1.04-34 Study on Treatment of Stage IV Solid Tumors with Mutant Neoantigen Specific T Cells
Authors: S. Qi, J. Song, S. Shengjie, Q. Boyu, Z. Xiaoling, H. Sun, Y. Wang, Y. Guan, X. Xia, Y. Xin, J. Shunchang
Journal: Journal of Thoracic Oncology (2018)